SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO-B) today announced that NICE (National Institute for Health and Clinical Excellence) this week has published draft guidelines recommending (http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsOnDraftGuidanceRecommendingAsthmaTests.jsp) the use of Aerocrine’s NIOX MINO®and NIOX VERO® to guide the diagnosis and treatment of a type of asthma caused by airway inflammation.
Help employers find you! Check out all the jobs and post your resume.
